Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Genetics
Volume 2014, Article ID 921240, 4 pages
http://dx.doi.org/10.1155/2014/921240
Case Report

A Case of Acute Myeloid Leukemia with a Previously Unreported Translocation (14; 15) (q32; q13)

1Hematology-Oncology Section, Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
2University of Oklahoma Health Sciences Center, Stephenson Cancer Center, 800 NE 10th Street, Oklahoma City, OK 73102, USA
3Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
4Department of Pediatrics, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

Received 31 July 2014; Revised 15 October 2014; Accepted 18 October 2014; Published 11 November 2014

Academic Editor: Philip D. Cotter

Copyright © 2014 Mohamad Khawandanah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. We hereby describe what we believe to be the first reported case of t (14; 15) (q32; q13) associated with acute myeloid leukemia (AML). Methods. PubMed, Embase, and OVID search engines were used to review the related literature and similar published cases. Case. A47-year-old female presented in December 2011 with AML (acute myelomonocytic leukemia) with normal cytogenetics; molecular testing revealed FLT-3 internal tandem duplication (ITD) mutation, while no mutations involving FLT3 D385/I836, NPM1 exon 12, or KIT exons 8 and 17 were detected. She was induced with 7 + 3 (cytarabine + idarubicin) and achieved complete remission after a second induction with high-dose cytarabine (HiDAC) followed by uneventful consolidation. She presented 19 months after diagnosis with relapsed disease. Of note, at relapse cytogenetic analysis revealed t (14; 15) (q32; q13), while FLT-3 analysis showed a codon D835 mutation (no ITD mutation was detected). She proved refractory to the initial clofarabine-based regimen, so FLAG-idarubicin then was used. She continued to have persistent disease, and she was discharged on best supportive care. Conclusion. Based on this single case of AML with t (14; 15) (q32; q13), this newly reported translocation may be associated with refractory disease.